IAS statement: Imbokodo trial must compel us to adequately resource efforts to find an HIV vaccine

Yesterday Johnson and Johnson and its global partners announced that they would discontinue the large-scale Imbokodo HIV Vaccine Trial.  Initial results showed that the vaccine did not provide significant protection against HIV infection in young women in sub-Saharan Africa. Despite this disappointing news, IAS – the International AIDS Society – emphasizes the importance of continued investment […]

18 May 2021 – HIV Vaccine Awareness Day

Today, the Journal of the International AIDS Society (JIAS) commemorates HIV Vaccine Awareness Day and reflects on the long-standing efforts to develop an HIV vaccine and the significance of SARS-CoV-2 vaccine development over the past year for the future of HIV vaccine research.

How HIV Vaccine R&D is enabling the rapid COVID-19 vaccine response

In this presentation, Dr. Roger Tatoud, presents the finding of an investigation led by the Enterprise to identify and characterize the ways in which HIV vaccine R&D has contributed to the early success of the COVID-19 vaccine response, the extent to which it has contributed across various dimensions, and the uniqueness of its contributions relative to other fields.